$MNPR insider trading

Over the last 12 months, Monopar Therapeutics insiders reported 1 buy totaling $105K and 5 sales totaling $36.2M across SEC Form 4 filings. 50% of those filings were made under pre-arranged 10b5-1 trading plans.

$105K
$36.2M
6
6
50%
Side
$100$1K$10K$100K$1.0MJun '26JulAug
Vu Quan Anh
RIOUX PATRICE
KLAUSNER ARTHUR J
Anderson Raymond
Tsuchimoto Kim R

All insider trades

Scroll the table sideways for price, value and marks.

Aug 26, 2026RIOUX PATRICE▼ Sale1$111.26$111
Aug 26, 2026Tsuchimoto Kim R▼ Sale4,090$111.39$456K-35.6%
Aug 25, 2026Anderson Raymond▼ Sale3,142$111.77$351K-11.7%
Dec 26, 2025Vu Quan Anh▲ Buy1,500$69.95$105K
Dec 18, 2025KLAUSNER ARTHUR J▼ Sale5,121$67.15$344K-36.9%
Sep 24, 2025Tactic Pharma LLC▼ Sale550,229$63.61$35.0M-66.9%

Every $MNPR filing on this page is one API call away

The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Monopar Therapeutics filings can reach your inbox instead.

Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $MNPR feed.

MNPR Insider Trading — Monopar Therapeutics Form 4 Buys & Sells | alphai